CEO that raised the price on AIDS medicine wishes he charged more

Because a 5000% rise in price wasn't enough for this greedy CEO.

45 seconds read time

It wasn't too long ago when Turing Pharmaceuticals' CEO cranked up the price on off-patent drug Daraprim, mostly used for people with AIDS and cancer, by a huge 5000%. Now, Martin Shkreli has said he wishes he raised it higher.

CEO that raised the price on AIDS medicine wishes he charged more |

Shkreli said: "I could have raised it higher and made more profits for our shareholders, which is my primary duty". During the Thanksgiving holiday, Turing released a press release saying the company had seen the error in its ways, and would be reducing the cost of Daraprim. But, it won't be doing that at all. Turing has said it will offer hospitals a 50% discount on the medicine (still up 2500%).

This is where it gets worse, with Shkreli adding: "My shareholders expect me to make the most profit. That's the ugly, dirty truth. I'm going to maximize profits. That's what people [in healthcare] are afraid to say".


Anthony joined the TweakTown team in 2010 and has since reviewed 100s of graphics cards. Anthony is a long time PC enthusiast with a passion of hate for games built around consoles. FPS gaming since the pre-Quake days, where you were insulted if you used a mouse to aim, he has been addicted to gaming and hardware ever since. Working in IT retail for 10 years gave him great experience with custom-built PCs. His addiction to GPU tech is unwavering and has recently taken a keen interest in artificial intelligence (AI) hardware.

Newsletter Subscription

Related Tags